Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Pancreatic cancer treatment efficacy is limited, necessitating novel therapeutic approaches like immunotherapy.
• MUC1, a tumor-associated antigen overexpressed in pancreatic cancer, is a potential immunotherapy target.
• Low immunogenicity of self-antigens like MUC1 due to immune tolerance hinders effective immunotherapy.

Purpose of the Study:

• To investigate the immunogenicity of an altered MUC1 epitope (MUC1_1068-1076Y1) compared to its wild-type (WT) form.
• To evaluate the potential of the altered MUC1 epitope as a target for pancreatic cancer immunotherapy.
• To assess the cross-recognition of pancreatic cancer cells by the altered MUC1 epitope.

Main Methods:

• Modification of MUC1_1068-1076 epitope amino acid residues to create MUC1_1068-1076Y1.
• Comparison of immunogenicity and CTL induction between altered and WT MUC1 epitopes.
• Assessment of HLA-A0201-restricted cross-recognition of pancreatic cancer cells and immune response induction via the perforin/granzyme pathway.

Main Results:

• The altered MUC1_1068-1076Y1 epitope demonstrated significantly higher immunogenicity than the WT MUC1_1068-1076 epitope.
• The altered epitope elicited a greater number of cytotoxic T lymphocytes (CTLs).
• MUC1_1068-1076Y1 cross-recognized pancreatic cancer cells expressing WT MUC1 peptides and induced stronger anti-cancer immune responses through the perforin/granzyme apoptosis pathway.

Conclusions:

• Altering MUC1 epitope residues can overcome low immunogenicity and break immune tolerance.
• The modified MUC1_1068-1076Y1 epitope is a promising HLA-A0201-restricted CTL target for pancreatic cancer immunotherapy.
• Epitope modification represents a feasible strategy to enhance anti-cancer immune responses against various human cancers.